Makoto Sahara

Title: Makoto Sahara: Innovator in Cardiac Regeneration

Introduction

Makoto Sahara is a prominent inventor based in Stockholm, Sweden. He has made significant contributions to the field of cardiac regeneration through his innovative research and patents. With a total of two patents to his name, Sahara is recognized for his work in identifying genetic markers that enhance the engraftment of human cardiac ventricular progenitor cells.

Latest Patents

Sahara's latest patents focus on genetic markers for engraftment of human cardiac ventricular progenitor cells. The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.

Career Highlights

Makoto Sahara is currently associated with Procella Therapeutics AB, where he continues to advance his research in cardiac health. His work has the potential to revolutionize treatments for heart diseases by improving the effectiveness of cardiac cell therapies.

Collaborations

Sahara collaborates with notable colleagues, including Chuen Yan Leung and Jonathan Clarke, who contribute to his research endeavors and help in the development of innovative solutions in the field of cardiac regeneration.

Conclusion

Makoto Sahara's contributions to the field of cardiac regeneration through his patents and research are noteworthy. His work on genetic markers for engraftment of human cardiac ventricular progenitor cells holds promise for future advancements in cardiac therapies.